Skip to main content
| News

Boehringer Ingelheim acquires Basel’s NBE-Therapeutics

10.12.2020

German pharma group Boehringer Ingelheim is to acquire the Basel life sciences company NBE-Therapeutics for €1.18 billion. NBE-Therapeutics specializes in the development of cancer therapies.

NBE-Therapeutics is to become part of Boehringer Ingelheim. The Basel company is being acquired for €1.18 billion. It will remain at its campus at the Technology Park Basel and operate as a new site within Boehringer Ingelheim’s R&D network. ”This transaction is a validation of our platform and its potential for the next generation cancer therapies,” said Bertrand Damour, Chief Executive Officer of NBE-Therapeutics, in a press release.

The Basel biotech company is focused on antibody-drug conjugates (ADC) and advancing targeted cancer therapies derived from its immune stimulatory platform. The lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors.

Boehringer Ingelheim is gaining access to an innovative and unique platform that will decisively expand its cancer immunology portfolio. “We welcome NBE-Therapeutics’ richly talented team to Boehringer Ingelheim and we look forward to collaborating with them on this important work,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors.

Boehringer Ingelheim expects to close the transaction in the first quarter of 2021.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
1 2 3 59

Do you have a question? We'd like to hear from you.